English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17419/19718 (88%)
Visitors : 6156649      Online Users : 797
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31121


    標題: OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKC delta/p53
    作者: Omari, Hany A.
    Tolba, Mai F.
    Hung, Jui-Hsiang
    Al-Tel, Taleb H.
    貢獻者: Sharjah Institute for Medical Research and College of Pharmacy, University of Sharjah
    Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University
    Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University
    School of Pharmacy, Chapman University, Irvine
    Department of Biotechnology, Chia Nan University of Pharmacy and Science
    關鍵字: OSU-2S
    sorafenib
    hepatocellular carcinoma
    cancer resistance
    PKCδ
    日期: 2016-11
    上傳時間: 2018-03-09 14:25:00 (UTC+8)
    出版者: Frontiers Media Sa
    摘要: Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating its drawbacks. OSU-2S, a PKCδ activator, was selected as a potential candidate anticancer agent to be combined with sorafenib to promote the anti-cancer activity through synergistic interaction.

    Methods: The antitumor effects of sorafenib, OSU-2S and their combination were assessed by MTT assay, caspase activation, Western blotting, migration/invasion assays in four different HCC cell lines. The synergistic interactions were determined by Calcusyn analysis. PKCδ knockdown was used to elucidate the role of PKCδ activation as a mechanism for the synergy. The knockdown/over-expression of p53 was used to explain the differential sensitivity of HCC cell lines to sorafenib and/or OSU-2S.

    Results: OSU-2S synergistically enhanced the anti-proliferative effects of sorafenib in the four used HCC cell lines with combination indices <1. This effect was accompanied by parallel increases in caspase 3/7 activity, PARP cleavage, PKCδ activation and inhibition of HCC cell migration/invasion. In addition, PKCδ knockdown abolished the synergy between sorafenib and OSU-2S. Furthermore, p53 restoration in Hep3B cells through the over-expression rendered them more sensitive to both agents while p53 knockdown from HepG2 cells increased their resistance to both agents.

    Conclusion: OSU-2S augments the anti-proliferative effect of sorafenib in HCC cell lines, in part, through the activation of PKCδ. The p53 status in HCC cells predicts their sensitivity toward both sorafenib and OSU-2S. The proposed combination represents a therapeutically relevant approach that can lead to a new HCC therapeutic protocol.
    關聯: Frontiers In Pharmacology, v.7, 463
    p53
    Appears in Collections:[生物科技系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    31121.pdf3475KbAdobe PDF181View/Open
    index.html0KbHTML271View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback